- Home
- AMBC vs MLYS Comparison
AMBC vs MLYS Comparison
Compare AMBC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBC
- MLYS
- Stock Information
- Founded
- AMBC 1991
- MLYS 2019
- Country
- AMBC United States
- MLYS United States
- Employees
- AMBC N/A
- MLYS N/A
- Industry
- AMBC Property-Casualty Insurers
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- AMBC Finance
- MLYS Health Care
- Exchange
- AMBC Nasdaq
- MLYS Nasdaq
- Market Cap
- AMBC 543.0M
- MLYS 526.1M
- IPO Year
- AMBC 1991
- MLYS 2023
- Fundamental
- Price
- AMBC $11.51
- MLYS $10.21
- Analyst Decision
- AMBC Strong Buy
- MLYS Strong Buy
- Analyst Count
- AMBC 2
- MLYS 2
- Target Price
- AMBC $17.00
- MLYS $30.00
- AVG Volume (30 Days)
- AMBC 431.2K
- MLYS 263.5K
- Earning Date
- AMBC 02-25-2025
- MLYS 03-20-2025
- Dividend Yield
- AMBC N/A
- MLYS N/A
- EPS Growth
- AMBC N/A
- MLYS N/A
- EPS
- AMBC N/A
- MLYS N/A
- Revenue
- AMBC $398,000,000.00
- MLYS N/A
- Revenue This Year
- AMBC N/A
- MLYS N/A
- Revenue Next Year
- AMBC N/A
- MLYS N/A
- P/E Ratio
- AMBC N/A
- MLYS N/A
- Revenue Growth
- AMBC 22.46
- MLYS N/A
- 52 Week Low
- AMBC $10.12
- MLYS $8.58
- 52 Week High
- AMBC $18.45
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- AMBC 45.24
- MLYS 44.53
- Support Level
- AMBC $11.35
- MLYS $9.57
- Resistance Level
- AMBC $11.72
- MLYS $10.79
- Average True Range (ATR)
- AMBC 0.31
- MLYS 0.64
- MACD
- AMBC 0.05
- MLYS 0.11
- Stochastic Oscillator
- AMBC 59.15
- MLYS 63.98
About AMBC Ambac Financial Group Inc.
Ambac Financial Group Inc is a financial services holding company. The business operations of the company include Legacy Financial Guarantee Insurance, Specialty Property and Casualty Insurance and Insurance Distribution. The Company has three reportable segments namely Legacy Financial Guarantee Insurance, Specialty Property and Casualty Insurance and Insurance Distribution. Majority of revenues are earned from Legacy Financial Guarantee Insurance segment.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.